Treatment of nail psoriasis with brodalumab: an open-label unblinded study.

Although nail involvement is common among patients with psoriasis and may significantly impair quality of life (QoL), treatment of nail psoriasis is still largely not standardized. Brodalumab is a recombinant, fully human, anti-interleukin-17 receptor A, monoclonal antibody, exhibiting long-term efficacy in plaque psoriasis, due to the concurrent inhibition of proinflammatory cytokines IL-17A, IL-17C, IL-17E, IL-17F and IL-17A/F heterodimer.1-2 The objective of this open-label, unblinded study was to evaluate its efficacy in nail psoriasis as assessed by the Nail Psoriasis Severity Index (NAPSI) and the Dermatology Life Quality Index (DLQI).